205 related articles for article (PubMed ID: 24168257)
1. Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.
de Bruijne J; Thomas XV; Rebers SP; Weegink CJ; Treitel MA; Hughes E; Bergmann JF; de Knegt RJ; Janssen HL; Reesink HW; Molenkamp R; Schinkel J
J Viral Hepat; 2013 Nov; 20(11):779-89. PubMed ID: 24168257
[TBL] [Abstract][Full Text] [Related]
2. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.
de Bruijne J; Bergmann JF; Reesink HW; Weegink CJ; Molenkamp R; Schinkel J; Tong X; Li J; Treitel MA; Hughes EA; van Lier JJ; van Vliet AA; Janssen HL; de Knegt RJ
Hepatology; 2010 Nov; 52(5):1590-9. PubMed ID: 20938912
[TBL] [Abstract][Full Text] [Related]
3. Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3/4A protease.
Wang H; Geng L; Chen BZ; Ji M
Biochem Cell Biol; 2014 Oct; 92(5):357-69. PubMed ID: 25178998
[TBL] [Abstract][Full Text] [Related]
4. Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b.
Vermehren J; Susser S; Lange CM; Forestier N; Karey U; Hughes E; Ralston R; Tong X; Zeuzem S; Sarrazin C
J Viral Hepat; 2012 Feb; 19(2):120-7. PubMed ID: 22239501
[TBL] [Abstract][Full Text] [Related]
5. Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.
Berger KL; Scherer J; Ranga M; Sha N; Stern JO; Quinson AM; Kukolj G
Antimicrob Agents Chemother; 2015 Oct; 59(10):6017-25. PubMed ID: 26195509
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
[TBL] [Abstract][Full Text] [Related]
7. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
McPhee F; Hernandez D; Yu F; Ueland J; Monikowski A; Carifa A; Falk P; Wang C; Fridell R; Eley T; Zhou N; Gardiner D
Hepatology; 2013 Sep; 58(3):902-11. PubMed ID: 23504694
[TBL] [Abstract][Full Text] [Related]
8. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
Forestier N; Larrey D; Guyader D; Marcellin P; Rouzier R; Patat A; Smith P; Bradford W; Porter S; Blatt L; Seiwert SD; Zeuzem S
J Hepatol; 2011 Jun; 54(6):1130-6. PubMed ID: 21145848
[TBL] [Abstract][Full Text] [Related]
9. Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment.
de Bruijne J; Sullivan JC; Kieffer TL; Botfield M; Shames B; Schinkel J; Molenkamp R; Weegink C; Reesink H
J Clin Virol; 2012 Feb; 53(2):174-7. PubMed ID: 22138301
[TBL] [Abstract][Full Text] [Related]
10. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
[TBL] [Abstract][Full Text] [Related]
11. Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon-α 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic Group.
Bai F; Yano Y; Kim SR; Seo Y; Miki A; Saito M; Hirano H; Momose K; Minami A; Hatazawa Y; Hayakumo T; Widasari DI; Rinonce HT; Sugano M; Tani S; Yoon S; Imoto S; Azuma T; Hotta H; Hayashi Y
Int J Mol Med; 2014 Jun; 33(6):1652-6. PubMed ID: 24647743
[TBL] [Abstract][Full Text] [Related]
12. Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals.
Nguyen LT; Gray E; Dean J; Carr M; Connell J; De Gascun C; Nguyen LA; O'Leary A; Bergin C; Hall W; Norris S
Antivir Ther; 2015; 20(8):865-9. PubMed ID: 25920764
[TBL] [Abstract][Full Text] [Related]
13. A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients.
Lawitz EJ; Hill JM; Marbury T; Demicco MP; Delaney W; Yang J; Moorehead L; Mathias A; Mo H; McHutchison JG; Rodriguez-Torres M; Gordon SC
Antivir Ther; 2013; 18(3):311-9. PubMed ID: 23047118
[TBL] [Abstract][Full Text] [Related]
14. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.
Kieffer TL; Sarrazin C; Miller JS; Welker MW; Forestier N; Reesink HW; Kwong AD; Zeuzem S
Hepatology; 2007 Sep; 46(3):631-9. PubMed ID: 17680654
[TBL] [Abstract][Full Text] [Related]
15. Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.
Larrat S; Vallet S; David-Tchouda S; Caporossi A; Margier J; Ramière C; Scholtes C; Haïm-Boukobza S; Roque-Afonso AM; Besse B; André-Garnier E; Mohamed S; Halfon P; Pivert A; LeGuillou-Guillemette H; Abravanel F; Guivarch M; Mackiewicz V; Lada O; Mourez T; Plantier JC; Baazia Y; Alain S; Hantz S; Thibault V; Gaudy-Graffin C; Bouvet D; Mirand A; Henquell C; Gozlan J; Lagathu G; Pronier C; Velay A; Schvoerer E; Trimoulet P; Fleury H; Bouvier-Alias M; Brochot E; Duverlie G; Maylin S; Gouriou S; Pawlotsky JM; Morand P
J Clin Microbiol; 2015 Jul; 53(7):2195-202. PubMed ID: 25926499
[TBL] [Abstract][Full Text] [Related]
16. Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C.
Sanjo M; Saito T; Ishii R; Nishise Y; Haga H; Okumoto K; Ito J; Watanabe H; Saito K; Togashi H; Fukuda K; Imai Y; El-Shamy A; Deng L; Shoji I; Hotta H; Kawata S
J Med Virol; 2010 Aug; 82(8):1364-70. PubMed ID: 20572079
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
Kwo PY; Lawitz EJ; McCone J; Schiff ER; Vierling JM; Pound D; Davis MN; Galati JS; Gordon SC; Ravendhran N; Rossaro L; Anderson FH; Jacobson IM; Rubin R; Koury K; Pedicone LD; Brass CA; Chaudhri E; Albrecht JK;
Lancet; 2010 Aug; 376(9742):705-16. PubMed ID: 20692693
[TBL] [Abstract][Full Text] [Related]
18. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes.
De Meyer S; Ghys A; Foster GR; Beumont M; Van Baelen B; Lin TI; Dierynck I; Ceulemans H; Picchio G
J Viral Hepat; 2013 Jun; 20(6):395-403. PubMed ID: 23647956
[TBL] [Abstract][Full Text] [Related]
19. Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256.
Mo H; Hedskog C; Lawitz E; Brainard DM; Yang J; Delaney W; Worth A; Miller MD
Antiviral Res; 2017 Apr; 140():151-157. PubMed ID: 28132867
[TBL] [Abstract][Full Text] [Related]
20. Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.
Sultanik P; Mallet V; Lagaye S; Casrouge A; Dorival C; Barthe Y; Fontaine H; Hézode C; Mottez E; Bronowicki JP; Carrat F; Theodorou I; Abel L; Gayat E; Fontanet A; Pol S; Albert ML;
Liver Int; 2015 Jul; 35(7):1833-44. PubMed ID: 25556540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]